---
title: "Annexon, Inc. (ANNX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ANNX.US.md"
symbol: "ANNX.US"
name: "Annexon, Inc."
industry: "Biotechnology"
datetime: "2026-06-14T02:29:35.604Z"
locales:
  - [en](https://longbridge.com/en/quote/ANNX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ANNX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ANNX.US.md)
---

# Annexon, Inc. (ANNX.US)

## Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.annexonbio.com](https://www.annexonbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.89 | 347 | - | - | - |
| PB | 3.77 | 292 | 4.78 | 4.04 | 1.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-04T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 2 | 20% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.71 |
| Highest Target | 27.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ANNX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ANNX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ANNX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ANNX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**